NLRP3 and metabolic dysfunction-associated steatohepatitis: Additionally, inhibition of the SHP-2/PI3K/NLRP3 axis has been reported to reduce pyroptosis and ameliorate non-alcoholic steatohepatitis [15], while SHP-2 has also been implicated in promoting pyroptosis and activating the NLRP3 inflammasome in renal cell carcinoma [9].